Search

Displaying results 6071 - 6080 of 10000 in total
  1. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.

    Synonyms: IN-A001
  2. Drug

    Diiodohydroxyquinoline

    go.drugbank.com/drugs/DB09115
    Approved

    Iodoquinol is not currently available in any FDA-approved products. … Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown.

  3. Drug

    Ozone

    go.drugbank.com/drugs/DB12510
    Investigational

    Ozone has been used in trials studying the treatment of Mild Asthma and Primary Apical Periodontite.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Lobeglitazone

    go.drugbank.com/drugs/DB09198
    Investigational

    Lobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. … It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells.

    Categories: Drugs Used in Diabetes
  5. Drug

    Fendiline

    go.drugbank.com/drugs/DB08980
    ApprovedWithdrawn

    Fendiline is a coronary vasodilator which inhibits calcium function in muscle cells in excitation-contraction coupling. It has been proposed as an antiarrhythmic and antianginal agent.

  6. Drug

    Ruplizumab

    go.drugbank.com/drugs/DB06475
    Investigational

    Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.

  7. Drug

    Vevorisertib

    go.drugbank.com/drugs/DB21481
    Investigational

    Vevorisertib has a monoisotopic molecular weight of 586.32 Da. … Vevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations

  8. Drug

    AZD-2836

    go.drugbank.com/drugs/DB06031
    Investigational

    AZD-2836 is an inhibitor of the nonstructural protein 5A (NS5A).[A264853] The drug is being investigated for treatment of hepatitis C because AZD-2836 has in vitro anti-HCV activity.[A264858]

    Synonyms: 6-(3,4-Dimethoxyphenyl)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]-4-quinazolinamine
  9. Drug

    Basiliximab

    go.drugbank.com/drugs/DB00074
    ApprovedInvestigational

    known as CD25 antigen) on the surface of activated T-lymphocytes. … A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also

  10. Drug

    Rofecoxib

    go.drugbank.com/drugs/DB00533
    ApprovedWithdrawn

    Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. … On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.